Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:

NCT ID: NCT05044273 Not yet recruiting - Clinical trials for Coronary Artery Disease

Evaluation of Effectiveness and Safety of Synergy XD Stent

IRIS SynergyXD
Start date: October 31, 2021
Study type: Observational [Patient Registry]

The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent in the "real world" daily practice as compared with the other drug-eluting stents.

NCT ID: NCT05041725 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Impact of Remimazolam for Postoperative Sedation on the Left Ventricular Systolic Performance in Cardiac Surgery

Start date: November 1, 2021
Phase: Phase 4
Study type: Interventional

This study analyzes the impact of intraoperative Remimazolam infusion for postoperative sedation on the left ventricular global longitude strain (LV-GLS) patients undergoing cardiac surgery

NCT ID: NCT05041218 Not yet recruiting - Clinical trials for Coronary Artery Disease

Neural Interfaces to Monitor Fatigue and Sleepiness in the Cathlab

Start date: October 1, 2021
Study type: Observational [Patient Registry]

Improvement of patients' care and outcome is largely based on development and validation of drugs and technologies, especially in rapidly evolving fields as Interventional Cardiology. In fact, even though the optimal efficiency of a cathlab can be influenced by Interventional Cardiologist's mental workload, stress' accumulation and performance, little if any attention is paid to the monitoring and optimization of his/her mental status. Electroencephalogram (EEG)-based neural-interfaces are able to estimate workload, fatigue and the degree of sleepiness through spectral analysis techniques. In particular, the amplitude of alpha waves is a widely validated indicator of mental engagement's level. Developing a low cost and highly feasible device to monitor and analyze operator's mental engagement level and performance could be extremely appealing, especially considering both the lack of data in literature for interventional disciplines and the recent technology developments.

NCT ID: NCT05039567 Not yet recruiting - Clinical trials for Coronary Artery Disease

Effect of an Optimal Heart Team Protocol on Decision-making Stability

Start date: October 2021
Phase: N/A
Study type: Interventional

This study is aimed to evaluate the effect of the optimal heart team implementation protocol on the stability of decision-making for patients with complex coronary artery disease.

NCT ID: NCT05037799 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Optimization of Image Quality for Myocardial Perfusion Imaging With Rubidium-82 PET in Patients With Known or Suspected Ischemic Heart Disease

Start date: October 1, 2021
Study type: Observational [Patient Registry]

Selection of the appropriate administered activity for each patient's body habitus is very important to obtain diagnostic image quality. Current SPECT imaging guidelines suggest "…an effort to tailor the administered activity to the patient's habitus and imaging equipment should be made… [however] strong evidence supporting one particular weight-based dosing scheme does not exist." An increase in body weight leads to higher fractions of attenuated and scattered photons, resulting in lower quality PET images for a given injected activity. Weight-based tracer dosing is commonly recommended as a solution in whole-body PET imaging with F-18-FDG. In contrast, Rb-82 PET imaging has traditionally been performed using a single dose (e.g. 40 mCi) administered for all patients but this is known to result in lower count-density and image quality in larger patients. This effect can be mitigated to some degree by administration of Rb-82 activity as a proportion of body weight while maintaining accuracy for the detection of disease. The objective of this project is to determine whether Rb-82 activity administered as a squared function of patient weight (quadratic dosing) can standardize PET myocardial perfusion image quality over a wide range of body weights. Sequential patients referred for dipyridamole stress Rb-82 PET perfusion imaging at the University of Ottawa Heart Institute. Patients will be divided into 4 weight groups to determine if there are significance differences in image quality or accuracy of injected Rb-82 activity between patients. Twelve (12) patients will be recruited in each of the 4 weight groups (3 in each 10 kg interval) to uniformly sample the full range of patient weights from 30 to 190 kg. Based on the previous oncology PET literature image quality is not expected to change as a function of weight, i.e. SNR and CNR will be proportional to weight0 (no weight-dependence) with quadratic dosing of Rb-82. Two operators will perform the PET image analysis as described above.

NCT ID: NCT05037695 Recruiting - Clinical trials for Coronary Artery Disease

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)

Start date: July 21, 2021
Phase: Phase 4
Study type: Interventional

Patients with type 2 diabetes mellitus (DM) have higher risk of major cardiovascular events (MACE) and renal disfunction. The Sodium-glucose cotransporter-2 inhibitors (iSGLT2) reduces hyperglycemia in patients with type 2 DM and have multiple metabolic effects, lowering primary composite cardiovascular outcomes and progression to renal failure. 25% of patients with Stable Ischemic Heart Disease (SIHD) undergoing PCI are diabetics being one of the most prevalent and important risk factors for the development of contrast induced nephropathy (CIN). The occurence of CIN is associated with higher rates of death, loss of renal function, necessity of dialysis and increase of health care costs. In this pilot study we sought to evaluate if the iSGLT2 would prevent periprocedural complications - such as periprocedural CIN and MI - in type 2 DM patients undergoing PCI through the assessment of renal and myocardial biomarkers

NCT ID: NCT05035056 Recruiting - Clinical trials for Coronary Artery Disease

WARRIOR Ancillary Study for CCTA Analysis

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

In this study, quantitative characterization of plaque using coronary computed tomographic angiography (CTA) will be used to determine if women who were treated with intensive medical therapy have a greater reduction in the amount and type of cholesterol plaque compared to women receiving usual care and if this results in beneficial changes in clinical symptoms. The study will provide an understanding of how intensive medical therapy works in providing clinical benefit in women with nonobstructive plaque.

NCT ID: NCT05034224 Recruiting - Clinical trials for Microvascular Coronary Artery Disease

Coronary Sinus Pressure and Microvascular Disease

Start date: August 23, 2021
Phase: N/A
Study type: Interventional

MACCHUS is a randomized, single-center, controlled, cross-over interventional study in which coronary artery resistances will be measured at baseline and during temporary occlusion of the coronary sinus.

NCT ID: NCT05033964 Not yet recruiting - Clinical trials for Coronary Artery Disease

The DESyne BDS Plus RCT: A Randomized Trial to Assess the Elixir DESyne BDS Plus DES for Treatment of Coronary Artery Lesions

Start date: September 2021
Phase: Phase 2
Study type: Interventional

The DESyne BDS Plus Randomized Clinical Study is a prospective, multi-center, single blind, randomized clinical study. Randomization (1:1; DESyne BDS Plus : DESyne X2) of up to 100 patients (50 in each arm) requiring treatment of up to two de novo coronary artery lesions ≤ 34 mm in length in vessels ≥ 2.25 mm and ≤ 3.5 mm in diameter will be conducted. Clinical endpoints will be assessed at each follow-up point: 3 days or hospital discharge (whichever comes first), 1, 6, and 12 months.

NCT ID: NCT05032937 Not yet recruiting - Clinical trials for Coronary Heart Disease

the Accuracy and Safety of Coronary Artery Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

Start date: September 1, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, prospective, controlled and diagnostic clinical trial which will enroll 30 patients scheduled for coronary angiography in China.Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.In order to evaluate the safety of polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in peripheral and tissue before and after the examination.The main indicators of the study are the degree of coronary artery stenosis and the stability of coronary atherosclerotic plaque assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.